Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
September 26, 2024 08:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment...
U.S. Biodefense Industry Research 2024-2030: Focus on Anthrax, Small Pox, Botulism, & Radiation/Nuclear
July 24, 2024 10:23 ET
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Biodefense Market Size, Share & Trends Analysis Report by Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), and Segment Forecasts,...
Biodefense Market Global Market Report 2023: Infectious Diseases Pose Mounting Threat to Global Health, Spurring Explosive Growth
May 18, 2023 06:03 ET
|
Research and Markets
Dublin, May 18, 2023 (GLOBE NEWSWIRE) -- The "Biodefense Market - Global Industry Analysis (2019 - 2022), Growth Trends, and Market Forecast (2023 - 2030)" report has been added to ...
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
September 26, 2022 16:12 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA®...
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
May 16, 2022 06:32 ET
|
Emergent BioSolutions
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded...
Biodefense Industry Trends and Opportunities 2021-2025 - Insights Into Anthrax, Smallpox, Botulism, and Other Applications
February 07, 2022 05:03 ET
|
Research and Markets
Dublin, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Biodefense Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The global biodefense market is projected to grow by...
Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
September 03, 2019 06:30 ET
|
Emergent BioSolutions
Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government’s continued efforts and long-term strategy to maintain...
Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
June 03, 2019 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...
Biodefense Market value to surpass $19 Billion by 2024: Global Market Insights, Inc.
January 30, 2019 04:09 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Canada biodefense market was valued at USD 349.3 million in 2017 and is expected to have considerable revenue size during the forecast...
Aphios Is Developing Pathogen Inactivation Technology For Human Plasma Units
September 26, 2018 08:00 ET
|
Aphios
WOBURN, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Heart Lung...